$11.8499
-0.1601[-1.33%]
At close: May 17
$11.8499
0[0.00%]
After Hours: 7:47PM EDT
Sage Therapeutics
(NASDAQ:SAGE)Sage Therapeutics Stock (NASDAQ:SAGE), Analyst Ratings, Price Targets, Predictions
Sage Therapeutics Inc has a consensus price target of $28.27, established from looking at the 100 latest analyst ratings. The last 3 analyst ratings were released from JP Morgan, HC Wainwright & Co., and Goldman Sachs on May 1, 2024, April 26, 2024, and April 26, 2024. With an average price target of $24 between JP Morgan, HC Wainwright & Co., and Goldman Sachs, there's an implied 102.53% upside for Sage Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
JP Morgan
HC Wainwright & Co.
Goldman Sachs
RBC Capital
Truist Securities
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Sage Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/01/2024 | Buy Now | 136.29% | JP Morgan | Anupam Rama | $29 → $28 | Maintains | Overweight | Get Alert |
| 04/26/2024 | Buy Now | 110.97% | HC Wainwright & Co. | Douglas Tsao | $28 → $25 | Maintains | Neutral | Get Alert |
| 04/26/2024 | Buy Now | 60.34% | Goldman Sachs | Salveen Richter | $28 → $19 | Maintains | Neutral | Get Alert |
| 04/26/2024 | Buy Now | 26.58% | RBC Capital | Brian Abrahams | $26 → $15 | Maintains | Sector Perform | Get Alert |
| 04/26/2024 | Buy Now | 51.9% | Truist Securities | Joon Lee | $22 → $18 | Maintains | Hold | Get Alert |
| 04/26/2024 | Buy Now | 51.9% | Mizuho | Uy Ear | $20 → $18 | Maintains | Neutral | Get Alert |
| 04/26/2024 | Buy Now | 43.46% | Canaccord Genuity | Sumant Kulkarni | $21 → $17 | Maintains | Hold | Get Alert |
| 04/26/2024 | Buy Now | — | Needham | Ami Fadia | — | Reiterates | → Hold | Get Alert |
| 04/25/2024 | Buy Now | — | Needham | Ami Fadia | — | Reiterates | → Hold | Get Alert |
| 04/18/2024 | Buy Now | 60.34% | Scotiabank | George Farmer | $34 → $19 | Maintains | Sector Outperform | Get Alert |
| 04/18/2024 | Buy Now | 43.46% | Oppenheimer | Jay Olson | $25 → $17 | Maintains | Perform | Get Alert |
| 04/18/2024 | Buy Now | 35.02% | TD Cowen | Ritu Baral | $30 → $16 | Maintains | Buy | Get Alert |
| 04/18/2024 | Buy Now | — | Needham | Ami Fadia | — | Reiterates | → Hold | Get Alert |
| 04/17/2024 | Buy Now | 136.29% | HC Wainwright & Co. | Douglas Tsao | → $28 | Reiterates | Neutral → Neutral | Get Alert |
| 04/17/2024 | Buy Now | 102.53% | Wedbush | Laura Chico | → $24 | Reiterates | Neutral → Neutral | Get Alert |
| 04/17/2024 | Buy Now | 18.14% | B of A Securities | Tazeen Ahmad | $24 → $14 | Downgrade | Neutral → Underperform | Get Alert |
| 03/26/2024 | Buy Now | 144.73% | JP Morgan | Anupam Rama | $24 → $29 | Maintains | Overweight | Get Alert |
| 03/11/2024 | Buy Now | 119.41% | RBC Capital | Brian Abrahams | → $26 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 02/28/2024 | Buy Now | 85.66% | Morgan Stanley | Vikram Purohit | $20 → $22 | Maintains | Equal-Weight | Get Alert |
| 02/15/2024 | Buy Now | 136.29% | HC Wainwright & Co. | Douglas Tsao | $25 → $28 | Maintains | Neutral | Get Alert |
| 02/15/2024 | Buy Now | 119.41% | RBC Capital | Brian Abrahams | $21 → $26 | Maintains | Sector Perform | Get Alert |
| 12/18/2023 | Buy Now | 68.78% | Stifel | Paul Matteis | $22 → $20 | Maintains | Hold | Get Alert |
| 12/12/2023 | Buy Now | 77.22% | Deutsche Bank | Neena Bitritto-Garg | → $21 | Initiates | → Hold | Get Alert |
| 11/08/2023 | Buy Now | 77.22% | RBC Capital | Brian Abrahams | $22 → $21 | Maintains | Sector Perform | Get Alert |
| 11/08/2023 | Buy Now | 85.66% | Wedbush | Laura Chico | $21 → $22 | Maintains | Neutral | Get Alert |
| 10/13/2023 | Buy Now | 110.97% | Goldman Sachs | Salveen Richter | $22 → $25 | Maintains | Neutral | Get Alert |
| 09/08/2023 | Buy Now | 102.53% | B of A Securities | Tazeen Ahmad | $25 → $24 | Maintains | Neutral | Get Alert |
| 09/07/2023 | Buy Now | 68.78% | Mizuho | Vamil Divan | $19 → $20 | Maintains | Neutral | Get Alert |
| 09/07/2023 | Buy Now | 85.66% | RBC Capital | Brian Abrahams | $25 → $22 | Maintains | Sector Perform | Get Alert |
| 08/09/2023 | Buy Now | 85.66% | Goldman Sachs | Salveen Richter | $75 → $22 | Maintains | Neutral | Get Alert |
FAQ
What is the target price for Sage Therapeutics (SAGE)?
The latest price target for Sage Therapeutics (NASDAQ: SAGE) was reported by JP Morgan on May 1, 2024. The analyst firm set a price target for $28.00 expecting SAGE to rise to within 12 months (a possible 136.29% upside). 50 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Sage Therapeutics (SAGE)?
The latest analyst rating for Sage Therapeutics (NASDAQ: SAGE) was provided by JP Morgan, and Sage Therapeutics maintained their overweight rating.
When was the last upgrade for Sage Therapeutics (SAGE)?
The last upgrade for Sage Therapeutics Inc happened on March 13, 2023 when RBC Capital raised their price target to $60. RBC Capital previously had a sector perform for Sage Therapeutics Inc.
When was the last downgrade for Sage Therapeutics (SAGE)?
The last downgrade for Sage Therapeutics Inc happened on April 17, 2024 when B of A Securities changed their price target from $24 to $14 for Sage Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Sage Therapeutics (SAGE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sage Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sage Therapeutics was filed on May 1, 2024 so you should expect the next rating to be made available sometime around May 1, 2025.
Is the Analyst Rating Sage Therapeutics (SAGE) correct?
While ratings are subjective and will change, the latest Sage Therapeutics (SAGE) rating was a maintained with a price target of $29.00 to $28.00. The current price Sage Therapeutics (SAGE) is trading at is $11.85, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.